BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
BrainStorm Cell Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.48M, down 33.1% year over year. For fiscal 2025 it was $4.18M, down 10.2% from the year before. Over ten years it grew -1.7% a year on average. The highest annual figure on record is $22.33M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18M | -10.2% |
| FY2024 | Dec 31, 2024 | $4.65M | -56.7% |
| FY2023 | Dec 31, 2023 | $10.75M | -23.0% |
| FY2022 | Dec 31, 2022 | $13.96M | -8.4% |
| FY2021 | Dec 31, 2021 | $15.24M | -31.8% |
| FY2020 | Dec 31, 2020 | $22.33M | +29.8% |
| FY2019 | Dec 31, 2019 | $17.20M | +107.5% |
| FY2018 | Dec 31, 2018 | $8.29M | +748.8% |
| FY2017 | Dec 31, 2017 | $977.00K | -56.6% |
| FY2016 | Dec 31, 2016 | $2.25M | -54.5% |
| FY2015 | Dec 31, 2015 | $4.95M | +3.7% |
| FY2014 | Dec 31, 2014 | $4.77M | +63.6% |
| FY2013 | Dec 31, 2013 | $2.92M | +64.8% |
| FY2012 | Dec 31, 2012 | $1.77M | +4.8% |
| FY2011 | Dec 31, 2011 | $1.69M | +61.6% |
| FY2010 | Dec 31, 2010 | $1.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $963.00K | -14.0% |
| Q1 FY2026 | Mar 31, 2026 | $762.00K | -41.6% |
| Q4 FY2025 | Dec 31, 2025 | $852.00K | -50.6% |
| Q3 FY2025 | Sep 30, 2025 | $899.00K | -14.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.12M | +21.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.30M | +35.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.72M | +1.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.05M | -68.6% |
| Q2 FY2024 | Jun 30, 2024 | $922.00K | -67.0% |
| Q1 FY2024 | Mar 31, 2024 | $961.00K | -67.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.70M | -30.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.33M | -11.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.79M | -45.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.92M | +11.8% |
| Q4 FY2022 | Dec 31, 2022 | $2.45M | -33.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.78M | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.11M | +42.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.62M | -39.7% |
| Q4 FY2021 | Dec 31, 2021 | $3.68M | -58.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.62M | +93.8% |
| Q2 FY2021 | Jun 30, 2021 | $3.60M | -36.8% |
| Q1 FY2021 | Mar 31, 2021 | $4.34M | -27.0% |
| Q4 FY2020 | Dec 31, 2020 | $8.82M | +42.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.87M | -53.4% |
| Q2 FY2020 | Jun 30, 2020 | $5.69M | +60.2% |
| Q1 FY2020 | Mar 31, 2020 | $5.95M | +72.1% |
| Q4 FY2019 | Dec 31, 2019 | $6.19M | +60.3% |
| Q3 FY2019 | Sep 30, 2019 | $4.01M | +102.9% |
| Q2 FY2019 | Jun 30, 2019 | $3.55M | +140.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.46M | +253.7% |
| Q4 FY2018 | Dec 31, 2018 | $3.86M | +230.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.98M | +354.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.48M | +57.4% |
| Q1 FY2018 | Mar 31, 2018 | $977.00K | +202.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.17M | +47.8% |
| Q2 FY2017 | Jun 30, 2017 | $435.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $941.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $323.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $790.00K | – |
See a number that looks wrong?